Home › Funds › Novo Holdings A/S › AVBP
Novo Holdings A/S position in AVBP
ARRIVENT BIOPHARMA INC · Health Care
Novo Holdings A/S reported holding 1,175,000 shares of AVBP (ARRIVENT BIOPHARMA INC) in its Q3 2026 13F filing — a position valued at US$35.6M, representing 2.39% of its reported portfolio and ranking #13 among its reported holdings. Novo Holdings A/S has disclosed AVBP holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Novo Holdings A/S's AVBP position evolved
Novo Holdings A/S first disclosed a stake in AVBP in Q1 2024 at 1,077,140 shares (US$19.2M). The position peaked in Q2 2026 at 1,500,000 shares, worth US$52.1M. Across 11 filings, Novo Holdings A/S increased the stake 4 time(s), trimmed it 2 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 1,175,000 shares valued at US$35.6M — a reduction of -325,000 shares quarter over quarter.. Notable position changes include a 39% increase in Q2 2024 (shares rose 27% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 1.08M | $19.24M | New |
| Q2 2024 | 1.50M | $27.82M | Add |
| Q3 2024 | 1.51M | $35.37M | Hold |
| Q4 2024 | 1.52M | $40.51M | Add |
| Q1 2025 | 1.87M | $34.62M | Add |
| Q2 2025 | 1.87M | $40.76M | Hold |
| Q3 2025 | 1.94M | $35.83M | Add |
| Q4 2025 | 1.94M | $39.08M | Hold |
| Q1 2026 | 1.94M | $44.81M | Hold |
| Q2 2026 | 1.50M | $52.11M | Reduce |
| Q3 2026 | 1.18M | $35.58M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AVBP and 13F data
AVBP (ARRIVENT BIOPHARMA INC) is a Health Care company. 51 other funds we track also report a position in AVBP — the largest reported positions include MONTANOVA CAPITAL, LLC (US$149.1M), INFINITUM ASSET MANAGEMENT, LLC (US$137.0M), Hillhouse Capital (HHLR Advisors) (US$119.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AVBP
- MONTANOVA CAPITAL, LLC 4.93M sh · $149.15M · Q3 2026
- INFINITUM ASSET MANAGEMENT, LLC 4.52M sh · $136.98M · Q3 2026
- Hillhouse Capital (HHLR Advisors) 3.93M sh · $118.97M · Q3 2026
- ORBIMED ADVISORS LLC 3.03M sh · $91.67M · Q3 2026
- Octagon Capital Advisors LP 2.14M sh · $64.84M · Q3 2026
- Vivo Capital, LLC 1.79M sh · $54.11M · Q3 2026
- Sofinnova Investments, Inc. 1.70M sh · $51.38M · Q3 2026
- General Catalyst Group Management, LLC 1.49M sh · $45.26M · Q3 2026
- Logos Global Management LP 1.35M sh · $40.88M · Q3 2026
- HSG Holding Ltd 663.31K sh · $20.08M · Q3 2026
- Foresite Capital Management VI LLC 490.34K sh · $14.85M · Q3 2026
- Seven Fleet Capital Management LP 451.17K sh · $13.66M · Q3 2026
More on Novo Holdings A/S
FAQ
How long has Novo Holdings A/S held AVBP?
Novo Holdings A/S has disclosed AVBP holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
What is Novo Holdings A/S's current position in AVBP?
As of Q3 2026, Novo Holdings A/S holds 1.18M shares of AVBP (ARRIVENT BIOPHARMA INC), valued at $35.58M, representing 2.39% of its reported portfolio and ranking #13.
Has Novo Holdings A/S been buying or selling AVBP?
In the latest 13F filing (Q3 2026), Novo Holdings A/S reduced its position in AVBP. The position peaked in Q2 2026 at 1.50M shares.
Which other funds hold AVBP?
Other major institutional holders of AVBP include MONTANOVA CAPITAL, LLC, INFINITUM ASSET MANAGEMENT, LLC, Hillhouse Capital (HHLR Advisors), among 51 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.